Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent obtained.~* Has ECOG (Eastern Cooperative Oncology Group) performance status of 0, 1 or 2 at the time of the randomisation.~* Has definitive histologically or cytologically confirmed adenocarcinoma of the colon or rectum.~* RAS status must have been determined (mutant or wild).~* Has at least one measurable metastatic lesion.~* No previous systemic anticancer therapy for unresectable metastatic colorectal cancer.~* Previous adjuvant (or neoadjuvant for patients with rectal cancer) chemotherapy is allowed only if if it has been completed more than 6 months before start of study treatment.~* Patient is not a candidate for combination chemotherapy with irinotecan or oxaliplatin, or for curative resection of metastatic lesions.~* Is able to take medication orally (i.e., no feeding tube).~* Has adequate organ function.~* Coagulation parameters in normal limit (or in therapeutic limit for patients treated with anticoagulant drugs).~* Women of childbearing potential must have been tested negative in a serum pregnancy test. Female participants of childbearing potential and male participants with partners of childbearing potential must agree to use a highly effective method of birth control. Women and female partners using hormonal contraceptive must also use a barrier method.~Exclusion Criteria:~* Is a pregnant or lactating female.~* Has certain serious illness or serious medical condition(s) as described in the protocol.~* Has had certain other recent treatment e.g. major surgery, field radiation, received investigational agent, within the specified time frames prior to randomisation.~* Has previously received Trifluridine/tipiracil or history of allergic reactions attributed to compounds of similar composition to Trifluridine/tipiracil or any of its excipients.~* Has rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption.~* Has contra-indication to bevacizumab or capecitabine.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Trifluridine/tipiracil + bevacizumab (Type: EXPERIMENTAL): Trifluridine/tipiracil (S95005): film-coated tablets containing 15mg of trifluridine and 7.065mg of tipiracil hydrochloride, or 20mg of trifluridine and 9.42mg of tipiracil hydrochloride.~Bevacizumab: concentrate for solution for IV infusion containing 25mg/ml of bevacizumab.~Trifluridine/tipiracil was administered at 35 mg/m2/dose orally within 1 hour after completion of morning and evening meals, for 5 days on/2 days off, over 2 weeks, followed by a 14-day rest period, with bevacizumab administered intravenously at the dose of 5 mg/kg every 2 weeks at Day 1 and Day 15.This treatment cycle was repeated every 4 weeks.
- Capecitabine + bevacizumab (Type: ACTIVE_COMPARATOR): Capecitabine was administered at 1250 mg/m² orally BID (bis in die)on Days 1-14 of each cycle, with bevacizumab (7.5 mg/kg, IV) administered on Day 1 of each cycle. This treatment cycle was repeated every 3 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).